Put companies on watchlist
Eckert & Ziegler Strahlen- und Medizintechnik AG
ISIN: DE0005659700
WKN: 565970
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Eckert & Ziegler Strahlen- und Medizintechnik AG · ISIN: DE0005659700 · EQS - Company News (122 News)
Country: Germany · Primary market: Germany · EQS NID: 1772143
14 November 2023 07:45AM

Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023


EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): 9 Month figures
Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023

14.11.2023 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 14 November 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month result was around € 2 million higher than the previous year's figure. In addition, there was an increase in expenses for future projects in the field of nuclear medicine diagnostics and therapy.

In the Medical segment, sales of € 82.8 million were around € 17.6 million or 27% higher than in the previous year. The main growth driver continues to be business with pharmaceutical radioisotopes, while sales of laboratory equipment and in the plant engineering division also continued to increase.

At € 101.0 million, the Isotope Products segment generated slightly higher external sales of € 0.5 million than in the first nine months of 2022. The segment's sales thus remained stable.

The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of around € 230 million and net income of around € 25 million.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz323e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

 



14.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1772143

 
End of News EQS News Service

1772143  14.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1772143&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Eckert & Ziegler Strahlen- und Medizintechnik AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.